Clonal OmpK35 truncation and incomplete genotype-phenotype correlation underlie cefiderocol resistance in carbapenem-resistant, hypervirulent Klebsiella pneumoniae from Romania
This study characterizes a convergent, cefiderocol-resistant, carbapenem-resistant hypervirulent *Klebsiella pneumoniae* lineage (primarily ST383) circulating in both outpatient and inpatient settings in Romania, revealing that clonal OmpK35 truncation and incomplete genotype-phenotype correlation underlie the observed resistance mechanisms.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the invisible world of bacteria, survival is a constant arms race. When humans use antibiotics to kill infections, the bacteria evolve defenses, often by acquiring genes that act like shields or molecular scissors to cut the drugs apart. One of the most dangerous players in this game is a bacterium called Klebsiella pneumoniae. It is a common cause of hospital infections, but a specific, terrifying version has emerged: a strain that is both hypervirulent, meaning it causes severe disease in healthy people, and resistant to nearly all standard antibiotics, including the powerful "last-resort" drugs used when everything else fails. Scientists are particularly worried about a new class of drugs called siderophore-cephalosporins, which are designed to trick bacteria into letting them inside by mimicking iron-transporting molecules. The question facing researchers is whether these new drugs can still stop the evolving superbugs, or if the bacteria have already found a way to block them.
A team of researchers in Romania recently set out to answer this question by looking closely at a group of Klebsiella pneumoniae samples taken from patients in Bucharest. These patients had all been in a hospital at some point, but the group included people who were treated as outpatients, those in general wards, and those in intensive care. The scientists wanted to understand the genetic makeup of these bacteria, specifically how they had become resistant to the newest antibiotic, cefiderocol, and whether the bacteria's genetic code could perfectly predict how strong their resistance would be. They used a modern technique that reads the entire genetic blueprint of the bacteria to find the specific mutations and genes responsible for their survival.
The study revealed that the bacteria in this group were not a random mix of different types. Instead, they were dominated by two main family lines, or clones. One of these lines, known as ST383, was particularly concerning. It carried a dangerous combination of traits: it was resistant to carbapenems, a major class of antibiotics, and it also carried a specific set of virulence genes that make the bacteria more aggressive and better at stealing iron from the human body. This "convergence" of extreme resistance and extreme virulence was found in eight of the samples, and it was linked to a specific genetic signature that included a gene called armA, which makes the bacteria resistant to a whole class of drugs called aminoglycosides. The researchers found that whenever the bacteria had the virulence genes, they also had this aminoglycoside resistance gene, suggesting they were inherited together on the same genetic package. This means that for these specific bacteria, a common treatment option involving aminoglycosides is likely useless from the start.
Perhaps the most striking discovery was that every single one of the twenty-five bacteria tested was resistant to cefiderocol, the drug designed to be a last line of defense. The bacteria had achieved this resistance through two main tricks. First, many of them carried genes that produce enzymes capable of breaking down the drug. Second, and crucially, they had damaged a specific doorway on their cell surface called OmpK35. This doorway is usually used by the bacteria to let things in, but the bacteria had mutated it so that it was broken or missing, preventing the drug from entering. The researchers found that in one family line, ST101, this broken doorway was a shared family trait, inherited from a common ancestor. In the other family line, ST383, the broken doorway appeared to have happened independently several times, suggesting that the bacteria were constantly under pressure to break this door to survive.
However, the study also uncovered a frustrating reality for doctors trying to treat these infections. While the scientists could identify the broken doorways and the resistance genes, the genetic code did not tell the whole story. Two bacteria that looked identical in every way genetically, with the same broken doors and the same resistance genes, showed different levels of resistance to the drug. One might be four times harder to kill than the other, even though their DNA looked the same. This means that simply reading the bacteria's genetic code is not enough to know exactly how strong the infection will be or how much drug is needed to stop it. The researchers also found that a common, quick lab test used to detect these resistance genes was wrong in nearly one out of six cases, sometimes missing the resistance or misidentifying the type of gene present.
The findings suggest that this dangerous, resistant, and virulent strain of bacteria is not just a problem for patients in intensive care units. It is circulating widely, moving between hospitals and outpatient settings, and bridging the gap between different types of medical care. The bacteria have evolved multiple ways to block the newest antibiotics, and their genetic code, while informative, cannot yet predict the exact strength of their defense. The researchers conclude that to stay ahead of these infections, surveillance needs to look beyond just the hospital inpatients and include a broader view of where these bacteria are traveling. They also emphasize that while genetic testing is a powerful tool, it must be paired with direct testing of how the bacteria react to drugs, because the genes alone do not tell the full story of the battle between the patient and the infection.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.